HUTCHMED (China) To Launch Oral CRC Drug in Japan With Takeda; Shares Slide 3%
Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market
hutchmed (china) will receive a milestone payment for FRUZAQLA (00013.HK).
hutchmed (china) (00013.HK) announced that following the pricing approval of FRUZAQLA 1mg/5mg capsules in japan and its commercial launch by its partner Takeda (TAK.US) for the treatment of previously treated metastatic colorectal cancer patients, the drug will receive a milestone payment. Earlier, FRUZAQLA had obtained production and sales approval from the Japanese Ministry of Health, Labour and Welfare (MHLW). This drug is the first innovative oral targeted therapy approved for the treatment of metastatic colorectal cancer in japan in over a decade and has been approved for treating patients who cannot be completely cured, are inoperable, and have progressive disease after chemotherapy.
Hutchmed (China) (00013.HK) announced that FRUZAQLA (fruquintinib) was launched in Japan by Takeda.
On November 22, Gelonghui reported that hutchmed (china) (00013.HK) announced today that after FRUZAQLA (furuglifen) 1 mg / 5 mg capsules received pricing approval in Japan and was launched commercially by its partner Takeda (TSE: 4502/NYSE: TAK) for the treatment of patients with treated metastatic colorectal cancer, hutchmed (china) will receive a milestone payment. Earlier, FRUZAQLA had obtained manufacturing and sales approval from Japan's Ministry of Health, Labour and Welfare (MHLW). FRUZAQLA is the first oral drug approved for the treatment of metastatic colorectal cancer in Japan in over a decade.
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday
hutchmed (china) (00013.HK) appointed Hu Chaohong as an independent non-executive director and a member of the technical committee.
On November 20, Hutchmed (China) (00013.HK) announced today that Dr. Hu Chaohong has been appointed as an independent non-executive director and member of the Technology Committee of the company, effective from November 21, 2024. Dr. Hu has over 20 years of experience in therapeutic antibodies, antibody-drug conjugates, and vaccine development. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading multiple research and development programs. Dr. Hu's expertise spans from early discovery to clinical development and commercialization. She also has a successful track record in business development and establishing strategic partnerships (including licensing and collaborations) successfully.